FDA Rejects Johnson & Johnson's RA Drug Sirukumab, More Safety Data Needed Post author:Sam Post published:September 24, 2017 Post category:BioPharma September 25, 2017By Alex Keown, BioSpace.com Breaking… Source: BioSpace You Might Also Like Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017 Takeda Jumps Into the Land of CAR-T R&D With New Tie-Up September 4, 2017 Galectin Tanks as NASH Drug Flunks Phase IIb Trial December 4, 2017
Celgene ReleaseData Presented At 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers September 7, 2017
